Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease
Authors not listed
Eli Lilly and Company · 2026
Abstract
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Participants will enroll into either A1D-MC-AT01 (NCT07787182) or A1D-MC-AT02 (upcoming).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2026). A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease. <em>Eli Lilly and Company</em>. https://clinicaltrials.gov/study/NCT07787169
Vancouver
Anonymous. A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease. Eli Lilly and Company. 2026.
BibTeX
@misc{anon2026AMaste,
title = {A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease},
author = {Anonymous},
journal = {Eli Lilly and Company},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Eli Lilly and Company 2026
Open access · US-GOV
A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease
European Journal of Medicinal Chemistry 2021
Citation only
Alzheimer’s disease and its treatment by different approaches: A review
University of Campinas, Brazil 2008
Open access · US-GOV
Brasília Study on Healthy Aging
AbbVie 2022
Open access · US-GOV
A Phase 1, Randomized, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Emraclidine Following Multiple Oral Doses in Healthy Elderly Participants (Part A) and to Evaluate the Safety and Tolerability of Emraclidine in Participants With Dementia Due to Alzheimer's Disease (Part B)
Nature Reviews Neurology 2024
Preprint · OA
Is Alzheimer disease a disease?
Innovation in aging 2025
Open access · OA